 Hypothesis B1: During phase 2, there will be a difference between the two groups in the percentage of responders 50 or greater reduction in symptom severity with regards to anxious symptoms of MDD as measured by the 14-item Hamilton Anxiety Rating Scale HAM-A; response rates will be higher for the ziprasidone group. 